The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Seven-year OS analysis from ECHELON-1: brentuximab vedotin + AVD versus ABVD in Hodgkin lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, reviews the findings of the ECHELON-1 study (NCT01712490), which compared frontline treatment with brentuximab vedotin plus AVD (doxorubicin, vinblastine, dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in patients with Hodgkin lymphoma (HL). The analysis, conducted over a seven-year follow-up period, demonstrates a survival benefit with the addition of brentuximab vedotin, as evidenced by improved overall survival (OS). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ECHELON-1 study looked at using brentuximab vedotin, the antibody that is targeted against CD30 with a MMAE warhead on the back in combination with chemotherapy versus standard ABVD chemotherapy. And that trial originally showed a benefit for progression free survival for the combination with the BV plus AVD. But over time has actually shown an overall survival. So this particular presentation is reporting seven year follow up now for patients as far as overall survival is concerned...
ECHELON-1 study looked at using brentuximab vedotin, the antibody that is targeted against CD30 with a MMAE warhead on the back in combination with chemotherapy versus standard ABVD chemotherapy. And that trial originally showed a benefit for progression free survival for the combination with the BV plus AVD. But over time has actually shown an overall survival. So this particular presentation is reporting seven year follow up now for patients as far as overall survival is concerned. And notably overall survival has been very difficult to prove and show in Hodgkin lymphoma due to multiple other therapies that one can give. So showing that using a novel agent such as brentuximab vedotin with chemotherapy in the front line actually improves overall survival of patients overall. That is actually quite substantial and significant.
Read more...
